One in seven couples struggles to conceive. That's why fertility treatments are booming. The UK women's healthcare market forecast shows that fertility treatments are the fastest‑growing pharmaceutical segment, with a CAGR above 10%. Why the surge? Because women are delaying childbearing, and IVF is more accessible.

What's driving growth? Ovulation induction drugs (clomiphene, letrozole) and gonadotropins (Gonal‑F, Menopur) are the mainstays. The UK women's healthcare market analysis notes that the fastest‑growing end‑user segment is gynecology centers, which offer comprehensive fertility workups and treatments.

What's new? Add‑on treatments like endometrial scratching, genetic testing of embryos (PGT‑A), and AI‑powered embryo selection. But evidence for some add‑ons is weak.

The bottom line: if you're struggling to conceive, see a fertility specialist. IVF is expensive, but the NHS offers some funded cycles. And don't waste money on unproven add‑ons.